MXPA03001057A - Metodo para tratar desordenes relacionados con la angiogenesis. - Google Patents

Metodo para tratar desordenes relacionados con la angiogenesis.

Info

Publication number
MXPA03001057A
MXPA03001057A MXPA03001057A MXPA03001057A MXPA03001057A MX PA03001057 A MXPA03001057 A MX PA03001057A MX PA03001057 A MXPA03001057 A MX PA03001057A MX PA03001057 A MXPA03001057 A MX PA03001057A MX PA03001057 A MXPA03001057 A MX PA03001057A
Authority
MX
Mexico
Prior art keywords
related disorders
treating angiogenesis
angiogenesis
treating
derivatives
Prior art date
Application number
MXPA03001057A
Other languages
English (en)
Inventor
Gustav Graff
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of MXPA03001057A publication Critical patent/MXPA03001057A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se da a conocer el uso de los acidos 3-benzoilfenilacetico y sus derivados, que incluyen el nepafenac, para tratar desordenes relacionados con la angiogenesis, que incluyen los desordenes oftalmicos, tal como la retinopatia diabetica y la degeneracion macular exudativa.
MXPA03001057A 2000-08-14 2001-08-13 Metodo para tratar desordenes relacionados con la angiogenesis. MXPA03001057A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22513300P 2000-08-14 2000-08-14
PCT/US2001/025318 WO2002013804A2 (en) 2000-08-14 2001-08-13 Method of treating angiogenesis-related disorders using benzoyl phenylacetic acid

Publications (1)

Publication Number Publication Date
MXPA03001057A true MXPA03001057A (es) 2004-09-10

Family

ID=22843668

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001057A MXPA03001057A (es) 2000-08-14 2001-08-13 Metodo para tratar desordenes relacionados con la angiogenesis.

Country Status (19)

Country Link
US (1) US20020037929A1 (es)
EP (1) EP1309323B1 (es)
JP (2) JP5586117B2 (es)
KR (1) KR20030017653A (es)
CN (1) CN1447688A (es)
AR (1) AR030345A1 (es)
AT (1) ATE345123T1 (es)
AU (2) AU2001283337B2 (es)
BR (1) BR0113204A (es)
CA (1) CA2417282C (es)
DE (1) DE60124560T2 (es)
DK (1) DK1309323T3 (es)
ES (1) ES2275710T3 (es)
HK (1) HK1057331A1 (es)
MX (1) MXPA03001057A (es)
PL (1) PL366220A1 (es)
PT (1) PT1309323E (es)
WO (1) WO2002013804A2 (es)
ZA (1) ZA200300782B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003092669A2 (en) * 2002-05-03 2003-11-13 Alcon, Inc. Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac
KR20050043923A (ko) * 2002-09-16 2005-05-11 알콘 매뉴팩츄어링, 리미티드 혈관신생 치료를 위한 ｐｄｅ-ⅳ 저해제의 용도
WO2004043352A2 (en) * 2002-11-12 2004-05-27 Alcon, Inc. Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases
WO2004064828A1 (ja) 2003-01-21 2004-08-05 Senju Pharmaceutical Co., Ltd. ２−アミノ−３−(４−ブロモベンゾイル)フェニル酢酸含有水性液剤
ZA200703992B (en) * 2004-11-09 2009-08-26 Alcon Inc 5, 6, 7-Trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
FR2909876A1 (fr) * 2006-12-19 2008-06-20 Galderma Res & Dev S N C Snc Utilisation du nepafenac ou ses derives pour le traitement de desordres dermatologiques
US20100292289A1 (en) * 2007-11-30 2010-11-18 Ampla Pharmaceuticals Inc. Treatment of metabolic syndrome with novel amides
JP2011513229A (ja) * 2008-02-21 2011-04-28 イスタ・ファーマスーティカルズ・インコーポレイテッド 補助剤としての眼科用ｎｓａｉｄ
US8962686B2 (en) 2010-04-28 2015-02-24 The Chinese University Of Hong Kong Method and medication for prevention and treatment of ocular hypertension and glaucoma
US9630909B2 (en) 2013-06-27 2017-04-25 Mylan Laboratories Ltd Process for the preparation of nepafenac

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH577461A5 (es) * 1975-08-13 1976-07-15 Robins Co Inc A H
ZA805476B (en) * 1979-09-26 1981-11-25 Robins Co Inc A H 2-amino-3-benzoyl-phenylacetamides and cyclic homologues
US4313949A (en) * 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
US4254146A (en) * 1979-10-18 1981-03-03 A. H. Robins Company, Inc. 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters
IL61945A (en) * 1980-02-19 1984-09-30 Robins Co Inc A H 2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them
DE3026402A1 (de) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
US4503073A (en) * 1981-01-07 1985-03-05 A. H. Robins Company, Incorporated 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids
IL64724A0 (en) * 1981-02-17 1982-03-31 Robins Co Inc A H 2-amino-3-(halobenzoyl)-methylphenylacetic acids and esters and salts thereof and pharmaceutical compositions containing them
US4568695A (en) * 1983-12-07 1986-02-04 A. H. Robins Company, Incorporated 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor
US4683242A (en) * 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
CA1325382C (en) * 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
US5994379A (en) * 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use
US6207700B1 (en) * 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
WO2001028472A1 (en) * 1999-10-21 2001-04-26 Alcon Universal Ltd. Drug delivery device
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
AU1051201A (en) * 1999-11-11 2001-06-06 Wireless Methods Ltd. Remote switching and actuation of electrical devices

Also Published As

Publication number Publication date
BR0113204A (pt) 2006-02-21
HK1057331A1 (en) 2004-04-02
WO2002013804A3 (en) 2002-06-06
ATE345123T1 (de) 2006-12-15
EP1309323A2 (en) 2003-05-14
ZA200300782B (en) 2004-08-27
AU8333701A (en) 2002-02-25
DE60124560T2 (de) 2007-09-06
JP5586117B2 (ja) 2014-09-10
PT1309323E (pt) 2007-01-31
ES2275710T3 (es) 2007-06-16
JP2004520267A (ja) 2004-07-08
JP2012193214A (ja) 2012-10-11
CN1447688A (zh) 2003-10-08
CA2417282A1 (en) 2002-02-21
AR030345A1 (es) 2003-08-20
KR20030017653A (ko) 2003-03-03
AU2001283337B2 (en) 2006-06-15
DK1309323T3 (da) 2007-03-19
DE60124560D1 (de) 2006-12-28
US20020037929A1 (en) 2002-03-28
CA2417282C (en) 2009-12-22
PL366220A1 (en) 2005-01-24
EP1309323B1 (en) 2006-11-15
WO2002013804A2 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
MX9702349A (es) Usos de derivado de 9-deoxi prostaglandina para tratar glaucoma.
ATE319456T1 (de) Verwendung von tetracyclinen zur behandlung von störungen der meibomschen drüsen
WO1998010767A3 (en) Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
MXPA03001057A (es) Metodo para tratar desordenes relacionados con la angiogenesis.
WO1999045920A3 (en) The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
EA200300560A1 (ru) Улучшенный способ лечения
ES2192832T3 (es) Uso de compuestos macrolidos para tratar glaucoma.
WO2003024386A3 (en) Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
CY1106155T1 (el) Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους
PL370795A1 (en) Composition based on etyllinoleate and triethylcitrate for the treatment of seborrhea and acne
ATE359794T1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
WO2003002106A3 (en) Use of tyrosine kinase inhibitions for treating allergic diseases
MXPA05008561A (es) Uso de esteroides para tratar personas que sufren de trastornos oculares.
DE69534620D1 (de) Verfahren zur behandlung von augenerkrankungen
CY1106409T1 (el) Παραγωγα κινολινης
WO2002078681A3 (en) Method of treating ocular inflammatory and angiogenesis-related disorders using an amide derivative of flubiprofen or ketorolac
PT1131073E (pt) Uso de derivados de estaurosporina para o tratamento de doencas oculares neovasculares
UA66757C2 (en) Ophthalmologic composition of carbonic anhydrase inhibitors, method for treating or preventing macular edema or age-related macular degeneration
AU2001267864A1 (en) Remedial agent for optic nerve disease and the like
WO2003092669A3 (en) Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
CY1105976T1 (el) Μεθοδος αντιμετωπισης διαταραχων σχετιζομενων με αγγειογενεση
PT1330246E (pt) Utilizacao de derivados do acido hidroxieicosatetraenoico em cirurgia intraocular
UA39527A (uk) Спосіб лікування опіку очей

Legal Events

Date Code Title Description
FG Grant or registration